Iris Lazaro-Fernandez
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).
Journal: Cephalalgia : an international journal of headache
Published: July 06, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.
Journal: Cephalalgia : an international journal of headache
Published: June 19, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
Journal: Neurology
Published: May 27, 2026
Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project).
Journal: Cephalalgia : an international journal of headache
Published: April 01, 2026
Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache
Journal: Revista de neurologia
Published: February 20, 2026
ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice.
Journal: Brain and behavior
Published: February 13, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
Journal: Neurology
Published: January 28, 2026
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response.
Journal: The journal of headache and pain
Published: October 31, 2025
Changes in plasma glutamate in hemodialysis-related-headache patients: A pilot study.
Journal: Neurologia
Published: March 20, 2025
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 27, 2023
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study.
Journal: European journal of neurology
Published: August 30, 2023
RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine.
Journal: European journal of neurology
Published: August 30, 2023
Showing 1-12 of 12
Last Updated: 09/26/2026